Healthcare company Ainos has secured exclusive licences for ten invention patents and patent applications for its AI Nose and point-of-care-testing (POCT) technologies.

The patents have been acquired from Taiwan Carbon Nano Technology (TCNT), Ainos’ affiliate and product co-developer.

They are related to gas sensors and medical devices and cover multiple regions, including Germany, the US, China, Japan, and Taiwan.

TCNT agreed to assign the licences in exchange for Ainos’ common stock shares with a total value of nearly $5.4m.

Ainos board chairman, president, and CEO Chun-Hsien (Eddy) Tsai said: “I believe this licensing will bolster our AI Nose and POCT technologies as we advance our AI Nose and POCT pipeline, including progressing our leading volatile organic compounds (VOC) POCT candidate, Ainos Flora, and jointly developing a VOC sensing platform with our Japanese partners.

“We are also moving forward with the Next-Gen Ainos Flora with the implementation of NVIDIA CUDA, targeting Q3 for design completion and Q4 for clinical trial kickoff. This all-stock licensing structure aligns TCNT's interest with Ainos shareholders while preserving cash for our growth.”

Ainos’ Flora VOC POCT device is designed based on the company’s AI-powered digital nose (AI Nose) technology. The non-invasive, and discreet device uses digital nose sensors and AI pattern recognition to help women quickly detect vaginal infections or sexually transmitted infections (STIs) in home settings.

The company is engaged in developing AI-powered POCT and VELDONA low-dose interferon therapeutics.

Its clinical-stage product pipeline includes human orphan drugs, VELDONA human and animal oral therapeutics, and POCT solutions powered by its AI Nose technology platform.